Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT02433353
Other study ID # Bayne-Jones
Secondary ID
Status Withdrawn
Phase Phase 4
First received April 9, 2015
Last updated January 11, 2016
Start date January 2016
Est. completion date January 2016

Study information

Verified date January 2016
Source Bayne-Jones Army Community Hospital
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review BoardUnited States: Federal Government
Study type Interventional

Clinical Trial Summary

Approximately 150 active duty service members meeting Diagnostic and Statistical Manual version 5 (DSM-5) criteria for posttraumatic stress disorder (PTSD) and scoring 50 or above on the Clinician Administered PTSD Score for DSM-5 (CAPS-5) will be recruited. Qualifying participants will be randomized on a 1:1 basis to either the eye movement desensitization reprocessing (EMDR) plus venlafaxine XR group or the EMDR plus placebo group. Protocol will call for participants to complete 12 one-hour EMDR session while taking a venlafaxine XR/placebo dose of 150mg or 225mg for the entire 24 weeks. Both prescribers and therapists will be blinded and CAPS-5 assessments will be completed by an individual not involved in a participant's direct treatment. An unblinded pharmacist will dispense medication or placebo according the instructions of the prescriber and will count remaining tablets to measure compliance. All EMDR sessions will be recorded and will be reviewed by the principal investigator using a fidelity checklist. CAPS-5 will be administered after completion of EMDR and again at 6 months from the date of his/her first therapy session.


Description:

Approximately 150 active duty service members meeting DSM-5 criteria for PTSD and scoring 50 or above on the Clinician Administered PTSD Score for DSM-5 (CAPS-5) will be recruited for a prospective, randomized, double-blinded, controlled trial. Participants will be recruited via referral from other providers or self-referral from recruitment fliers. CAPS-5 is considered the gold-standard for PTSD symptom assessment in research. An initial PHQ-9,PCL-5, urine drug screen, and pregnancy test will be obtained at that visit as well. Qualifying participants will then meet with a prescriber, review informed consent, draw a number for randomization, and complete the SCID-5. The participant will then meet with the pharmacist who will dispense either venlafaxine XR or placebo. Randomization will have occurred before any participants have been recruited. Randomization will consist of use of a random number generator to generate 150 numbers. The pharmacist will secretly assign half of the numbers to treatment and half to control. Numbers generated will be written on slips of paper and placed in opaque envelopes then placed in a box. Participants will then draw their own numbers and inform the researchers of the number drawn. The titration schedule for the venlafaxine XR/placebo will be 3 days at 37.5mg, 7 days at 75mg, then increasing to 150mg. The participant will meet with the prescriber after 4 weeks at 150mg to determine if an increase to 225mg is warranted based on the participants DSM-5 PTSD symptoms. Meetings with a prescriber will then occur monthly throughout the study unless side effects or other concerns require more frequent follow up. Prescriber visits will be scheduled for 30 minutes, however, visits could be completed in as little as five minutes if the medication is working well with no side effects, blood pressure remains at baseline, the participant remains adherent to both medication and therapy, and the participant raises no concerns. Participants will meet with the pharmacist on a monthly basis for pill counts. EMDR sessions will occur weekly if possible and not any less than once every 2 weeks. Two sessions are allowed in 1 week if the participant anticipates going to the field or otherwise being unavailable for regular visits. All EMDR sessions will be recorded using a camcorder and the principal investigator will review 10% of all therapy sessions (a minimum of 1 session per participant) using a fidelity checklist. CAPS-5 assessments will be completed by an individual not involved in a participant's direct treatment and will be administered after completion of EMDR and again at 6 months from the date of his/her first therapy session. A urine drug screen will be ordered with each CAPS-5. Missing data/participant drop out will be handled using last object carried forward. Comparisons between interventions will be computed using a student's T-test for single comparisons between groups or ANOVA when multiple comparisons/time points are involved. If at any point a participant requests a record of treatment, a summary of care will be provided.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date January 2016
Est. primary completion date January 2016
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 17 Years to 70 Years
Eligibility Inclusion:

- Initial CAPS-5 score of 50 or greater

- Meeting criteria for PTSD using DSM-5 criteria

- Open to active duty US service members of all genders, races / ethnicities, religions, sexual orientations, and marital statuses

- Participants can have a history of mild TBI, past or current substance abuse, nicotine dependence, chronic pain, migraines/headaches, and most other medical illnesses not specified in exclusion section

- Participants can be taking opiates, a sleep aid, and/or prazosin for an indication of PTSD nightmares provided dosing does not exceed 15mg (men) / 9mg (women). Dosing more than once per day is not permitted

Exclusion:

- Current suicidal or homicidal ideation

- Pregnancy

- Profound hearing loss

- HIV and AIDS

- Current chemotherapy

- Primary thought disorders

- Bipolar disorder or cyclothymia

- Current substance dependence (not including nicotine)

- Current use of bupropion above 150mg daily

- Current use of mirtazapine above 15mg daily

- Current use of an SSRI

- Current use of another SNRI

- Current use of tricyclic antidepressants in doses above 50mg

- Current use of an MAO-I

- Current use of a stimulant

- Current use of a mood stabilizer/anti-epileptic for an indication of mood stability or reduction in anger

- Current use of an anti-psychotic

- Current use of lithium

- Chronic daily use of steroids

- Current use of tapentadol

- Current use of dronabinol

- Current use of ketamine

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Intervention

Drug:
Venlafaxine XR
Serotonin norepinephrine reuptake inhibitor
Behavioral:
EMDR
psychotherapy
Drug:
Placebo
Look-alike venlafaxine XR tablets containing no active drug

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Bayne-Jones Army Community Hospital

Outcome

Type Measure Description Time frame Safety issue
Primary Change in PTSD symptoms at 12 weeks measured using the CAPS-5 scale Clinician Administered PTSD Scale for DSM-5 12 weeks No
Primary Change in PTSD symptoms at 24 weeks measured using the CAPS-5 scale Clinician Administered PTSD Scale for DSM-5 24 weeks No
Secondary Change in depression symptoms at 12 weeks measured using the PHQ-9 scale Periodic Health Questionnaire 12 weeks No
Secondary Change in depression symptoms at 24 weeks measured using the PHQ-9 scale Periodic Health Questionnaire 24 weeks No
Secondary Percentage of participants experiencing adverse events as a measure of safety and tolerability 24 weeks No
Secondary Attrition percentage as a measure of safety and tolerability 24 weeks No
Secondary Change in PTSD symptoms at 12 weeks measured using the PCL-5 scale PTSD Checklist for DSM-5 12 weeks No
Secondary Change in PTSD symptoms at 24 weeks measured using the PCL-5 scale PTSD Checklist for DSM-5 24 weeks No
Secondary Presence of non-prescribed or illicit drugs on urine drug screen at 12 weeks 12 weeks No
Secondary Presence of non-prescribed or illicit drugs on urine drug screen at 24 weeks 24 weeks No
See also
  Status Clinical Trial Phase
Completed NCT03384706 - A Comparison of CPT Versus ART Versus WL N/A
Completed NCT03418129 - Neuromodulatory Treatments for Pain Management in TBI N/A
Completed NCT03129204 - Sensation Awareness Focused Training for Spouses N/A
Recruiting NCT05651295 - A Precision Medicine Approach to Target Engagement for Emotion Regulation N/A
Completed NCT05113277 - Development and Evaluation of a Tonic Immobility Focused Psychoeducational Intervention N/A
Recruiting NCT05327504 - Written Exposure Therapy for Veterans With SUD and PTSD N/A
Recruiting NCT05843695 - Enhancing Psychotherapy for Veterans and Service Members With PTSD and Anxiety N/A
Active, not recruiting NCT05530642 - An Augmented Training Program for Preventing Post-Traumatic Stress Injuries Among Diverse Public Safety Personnel N/A
Completed NCT00644423 - Omega-3 Fatty Acids and Post Traumatic Stress Disorder (PTSD) N/A
Completed NCT02989987 - NET for SGBV Survivors in Eastern DR Congo N/A
Completed NCT02320799 - Randomized Controlled Trial of Interpersonal Psychotherapy for Depression and PTSD Among HIV+ Women in Kenya N/A
Recruiting NCT02293291 - Thermal Clinic Treatment in Gulf War Illness Phase 1/Phase 2
Completed NCT02242136 - Treatment of Posttraumatic Stress Disorder and Aggressive Behavior in Soldiers and Ex-combatants N/A
Completed NCT01911585 - Efficacy of 60-minute Versus 90-minute Sessions in Treating PTSD Using Prolonged Exposure N/A
Completed NCT02720497 - The Efficacy of 90-Minute Versus 60-Minute Sessions of Prolonged Exposure for PTSD N/A
Completed NCT01693978 - Contingency Outcomes in Prolonged Exposure N/A
Terminated NCT01408641 - Topiramate for Alcohol Use in Posttraumatic Stress Disorder N/A
Completed NCT01469754 - Longitudinal Survey Analysis in Lymphoma Survivors N/A
Completed NCT02362477 - Telemental Health and Cognitive Processing Therapy for Female Veterans With Military-related PTSD Phase 3
Terminated NCT01239173 - Emotional Memory Reactivation in Posttraumatic Stress Disorder Phase 3